At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 100 enrolled
Drug / intervention
Rivastigminedrug
Likely dose
Rivastigmine 27 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, 16 Week, Phase IV Study to Evaluate Safety, Tolerability and Effectiveness in Patients With Severe Dementia of the Alzheimer's Type Exposed to Rivastigmine (Exelon)15cm2 Transdermal Patch
In Brief
A Phase 4 clinical trial evaluating Rivastigmine for Alzheimer's Disease. Completed, enrolled 100 participants across 9 sites.
Detailed Summary
This was a multicenter, prospective, phase IV study evaluating safety, tolerability and effectiveness of rivastigmine 27 mg -15 cm\^2 transdermal patch prescribed in patients with severe dementia of the Alzheimer's type as per discretion of treating physician.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesIndia
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartDec 2018
Primary CompletionDec 2022
Study CompletionDec 2022
TodayJul 2026
First PostedDec 12, 2016
Enrollment StartDec 31, 2018
Primary CompletionDec 7, 2022
Study CompletionDec 8, 2022
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 9.6 years ago
Interventions
Rivastigminedrug
15 cm\^2 patch sizes loaded with 27 mg of rivastigmine - one patch per day